Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. | Aplastic Anemia & MDS International Foundation Return to top.
  1. Education
  2. Research Articles
  3. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.

Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes.

Journal Title: 
J Clin Oncol
Primary Author: 
Garcia-Manero G
Author(s): 
Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, Maddipoti S, Godley LA, Gabrail N, Berdeja JG, Nadeem A, Kassalow L, Kantarjian H.
Original Publication Date: 
Monday, June 3, 2013
Full Article on PubMed: 
https://www.ncbi.nlm.nih.gov/pubmed/23733767/

No abstract available.

Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Share with addtoany.com.